Date Title  
Nov 30, 2023
Summary ToggleSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
 
Nov 28, 2023
Summary ToggleSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
 
Nov 09, 2023
Summary ToggleSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
 
Aug 30, 2023
Summary ToggleSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
 
Aug 10, 2023
Summary ToggleSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
 
Jun 06, 2023
Summary ToggleSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
 
May 12, 2023
Summary ToggleSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
 
Mar 20, 2023
Summary ToggleSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
 
Mar 10, 2023
Summary ToggleSol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
 
Jan 27, 2023
Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
 
Displaying 1 - 10 of 102 results